Cancer cells develop tactics to circumvent the interventions by desensitizing themselves to 12 interventions. The principle route of desensitization includes activation of survival pathways (e.g. NF-kB, 13 PARP) and downregulation of cell death pathways (e.g. CD95, ASK1). As a result, it requires high dose of 14 therapy to induce cell death which, in turn damages normal cells through the collateral effects. Methods are 15 needed to sensitize the low and non-responsive resistant tumor cells in order to evoke a better response 16 from the current treatments. Current treatments including chemotherapy can induce cell death only in bulk 17 cancer cells sparing low-responsive and resistant tumor cells. Here we report a novel tumor sensitizer 18 derived from the natural Vitamin E analogue (AMP-001). The drug design is based on a novel "A priori 19 activation of apoptosis pathways of tumor technology (AAAPT) which is designed to activate cell death 20 pathways and inhibit survival pathways simultaneously. It involves an inbuilt targeting vector which targets 21 tumor specific Cathepsin B, overexpressed by many cancers including gastric cancer. Our results indicate 22 that AMP-001 sensitizes gastric cancer cells which resulted in expanding the therapeutic index of front-line 23 chemotherapy doxorubicin both in vitro and in vivo nude mouse model. The synergy between AMP-001 24 and doxorubicin could pave a new pathway to use AMP-001 as a neoadjuvant to chemotherapy to achieve 25 a better efficacy and reduced off-target toxicity.
Introduction

27
Tumor cells have a remarkable ability to circumvent endogenous and exogenous toxicities by deactivating 28 cell death pathways and thereby desensitizing themselves to interventions 1 . Defects in apoptosis pathways 29 (e.g. CD95, APO-1/Fas) would make tumor cells insensitive to chemotherapy 2 . For example, loss of CD95 30 signaling pathway resulted in the development of cancer 3 and resistance to chemotherapy 4 . Restoration of 31 the apoptotic machinery with apoptosis inducing ligands (apoptogens) is an area of active investigation in the 32 drug development. Several agents have been developed to activate TRAIL 5 , to downregulate Bcl-2 6 and to 33 restore function of mutated p53 in order to sensitize tumor cells. Similarly, mitogen activated protein kinase 34 MAPK signaling pathways are also involved in desensitization of tumor cells. The advantage of sensitizing 35 tumor technology is to evoke a better response from the existing treatments in terms of reducing the 36 therapeutic dose without compromising efficacy and a potential reduction of dose related off-target toxicity.
37
Consequently, tumor sensitizing agents, potentially can be used as neoadjuvant to chemotherapy to expand 38 the therapeutic index of chemotherapy 7 .
39
Tumor sensitivity to chemotherapy in vivo is shown to be dependent on spontaneous baseline tumor 
45
The overall 5-year survival rates for the patient group with high AI (> 0.97) and low AI (< 0.97, p =0.001)
46
were 89.6 % and 69.2 % respectively 11 indicating that AI could be a potential biomarker of risk stratification of tumors/patients to see who responds better to which treatments.
48
We have developed a novel technology, "A priori Activation of Apoptosis Pathways of Tumor"
49
(AAAPT) as a strategy to sensitize low responsive tumor cells in order to evoke a better response from 50 chemotherapy 12 . The goal is to understand the molecular biology of desensitization tactics of tumor cells to 3 51 bypass the intervention by reactivating specific dysregulated apoptosis pathways selectively in tumor 52 sparing normal cells. Since ubiquitous or systemic activation of apoptosis can induce undesirable 53 neurodegeneration and myelosupression 13 , targeting is essential 14 .
54
Gastric cancer remains the second leading cause of cancer-related deaths in the world 15a . Almost two- 
88
Previous studies suggested that -tocopheryl succinate could destroy mitochondrial function and 89 cause the oxidative damage, resulting in over production of reactive oxygen species (ROS) and apoptosis.
90
Although, parent molecule -tocopheryl succinate (-TOS) showed promising anti-tumor properties in 91 vitro, studies in an immunocompetent mouse in vivo model showed that -TOS was not only ineffective at 92 the published doses, but resulted in severe side effects due to lack of targeting 23 . Elevated ROS levels can 93 render cancer cells more sensitive to agents that cause oxidative stress [24] [25] . There are many anti-cancer 94 drugs such as daunorubicin 26a , cisplatin 26b , paclitaxel 26c and trisenox 26d that can augment ROS production 95 in cancer cells, despite their inability to target cancer cells leading to non-specific side effects.
96
Here, we examined the effect of combining AMP-001 and doxorubicin for a potential synergistic 97 effect in human gastric cancer both in vitro and in vivo. These results indicate that low dose pretreatment 98 of tumor in vivo prepares tumor to make it sensitive to doxorubicin by showing a cumulative and significant 99 tumor regression compared to individual drugs. A potential mechanism of action is being suggested based 100 on the limited data.
101
Materials and Methods
102
Cell Culture and Treatment
103
The human gastric cancer cell lines MGC-803 and SGC-7901 were cultured in Dulbecco's modified
104
Eagle's medium (DMEM) supplemented with 10% FBS, 100 IU/ml penicillin, 100 μg/ml streptomycin in 105 a humidified atmosphere with 5% CO 2 at 37℃.
106 Reagents
107
The novel compound AMP-001 was designed and synthesized by Sci-Engi-Medco Solutions Inc 108 (SEMCO). AMP-001 was dissolved in distilled water and stored at -20℃ until use. The drug doxorubicin 109 was purchased from Sigma-Aldrich Biotechnology. For all AMP-001/DOX combinational treatment, 110 cancer cells were pretreated with AMP-001 before doxorubicin was added into the culture. All above 111 micromolecular reagents were dissolved and saved according to manufacturer specifications.
112
Cell Survival and Growth Assay
113
The detection of cell viability and cell growth were performed with cholecystokinin-8 (CCK-8) assay
114
(Dojindo, Japan). Briefly, 6000 viable gastric cancer cells were seeded in 96-well plates. After specific 115 treatment, each well was mixed with 10 l CCK-8 and incubated for additional 1h. The OD values were 116 detected at an absorbance of 450nm.
117
Flow Cytometry Analysis
118
MGC-803 and SGC-7901 were placed in 12 well plates overnight, and then treated with AMP-001.
119
Cells were then harvested, washed twice with pre-cold PBS, and evaluated for apoptosis by double staining Biotechnology, Nanjing, China) for 30min at 37℃, and then washed twice with PBS. Beckman flow 124 cytometer was used for final detection. Flow Jo vX.0.7 software was used to analyze the data.
125
Measurement of intracellular ROS level 126
The intracellular ROS level was measured by flow cytometry as described previously 24 . Briefly, 2×10 5 cells 127 were placed in 12 well plates, allowed to attach overnight, and exposed to the treatment needed. Cells were 128 stained with 10μM DCFH-DA (Sigma) at 37℃ for 30 min with serum free culture. Cells were washed twice 129 with pre-cold PBS and photographed or collected for fluorescence analysis using Beckman flow cytometer.
130
In some experiments, cells were pretreated with 5mM NAC for 2h prior exposure to compounds and 131 analyzed for ROS generation. 
132
Cell Mitochondria Isolation
193
Cells were plated into 6 well plates that percolated with 0.1% gelatin. This was defined as culture day 1
194
for the purpose of this study. Cell plating media was changed at day 3 to cell maintenance media and cell 9 195 maintenance media subsequently was changed three times a week. Day 5-7 cells were re-suspended with 196 trypsin and re-plated as desired density (>10,000) at 96 well plate which percolated with 0.1% gelatin.
197
Sample Preparation: 3.75 mg AMP-001 was dissolved into 0.25 ml water to create a 10 mM stock 
211
All experiments were performed at least three times. Data are presented as means ± SD. All 212 statistical analyses were performed using GraphPad Prism 6.0 (GraphPad, SanDiego, CA). One-way
213
ANONVA and Student's t-test were applied to determine statistical significance. A value of p<0.05 was 214 considered statistically significant. 
AMP-001 Induces Apoptosis and Potentiates Doxorubicin-Induced Apoptosis in Gastric Cancer
244
Cells.
245
The pro-apoptotic effect of AMP-001 was assessed using Annexin V/ staining assay. As shown in 246 Figure 2 , two gastric cancer cell lines SGC-7901 and MGC-803 showed significant apoptosis after 48h 247 treatment with IC-50 dose of AMP-001. Although AMP-001 itself was able to induce cell apoptosis, the 248 aim is to use it as a tumor sensitizer in conjunction with chemotherapy (e.g. doxorubicin) to see the potential 249 synergy with it. This will enable us to extend the sensitizing potential of AMP-001 to other FDA approved 250 chemotherapeutics used to treat other kinds of cancers. We, thus investigated whether the low dose of AMP- (Fig 3B) . In addition, combination treatment 261 of cancer cells with 10μM AMP-001 significantly reduced the IC 50 of doxorubicin in SGC-7901 and MGC-262 803 cells (~ 6.68 and 9.68 fold reduction, respectively) when compared with doxorubicin only treatment 263 (Fig 4 A-B) , thus, establishing the synergy between doxorubicin and AMP-001. These results will have a 264 broader connotation that potentially, one can reduce the chemotherapeutic dose clinically without As AMP-001 could induce human gastric cancer cells apoptosis at a decent dose, the potential 281 mechanism of cell death through reactive oxygen species (ROS) accumulation was investigated. As shown 282 in Fig. 5 A-B , pretreatment with AMP-001 for 24h before doxorubicin treatment in SGC-7901 and MGC-283 803 cells caused a significant increase in DCF-reactive ROS than doxorubicin alone. It is well known that 284 the excessive ROS generation causes oxidative stress and impairs membrane potential, resulting in 285 mitochondrial dysfunction [28] [29] . Hence, analysis of mitochondrial potential was carried out using 286 polychromatic dye JC-1 (5,59,6,69-tetrachloro-1,19,3,39-tetraethylbenzimidoazolylcarbocyanino iodide) 287 which forms red-orange clusters with high membrane potential mitochondria. while low membrane 288 potential mitochondria show green staining. The results revealed a significant decrease in mitochondrial 289 membrane potential through the enhanced monomer green fluorescence post combinational treatment 290 (12.1%) compared to individuals AMP-001 (2.1%) and doxorubicin (5.7%) ( Fig 5C) . 306 before adding doxorubicin and analyzed post 24 hrs. The results revealed clear increases in p-p38 MAPK, 307 p-JNK and p-ERK activity following the combination treatment compared with the control and with AMP-308 001 alone ( Fig 6A) . It is to be noted that AMP-001 and doxorubicin have incremental effect on these 309 activities. However, in combination with doxorubicin, there is a significant enhancement in the intensity 
322
The sensitizing potential of AMP-001 has paved the way for evoking a better response from 323 chemotherapy, particularly doxorubicin in vitro. Hence, it is may be essential if the same thing is true in an 324 in vivo situation. Doxorubicin either alone or in combination with AMP-001 were injected i.p in a xenograft 325 gastric cancer model in nude mice. MGC-803 cells were implanted subcutaneously in the right flank of 326 nude mice. After a week, the mice were randomized into 4 groups and treated as described in the 327 experimental protocol. Animals were sacrificed after 3 weeks treatment. We found that low dose (10 328 mg/Kg) AMP-001 alone did not inhibit the growth of the tumor at that dose compared to control, while 329 doxorubicin alone (1mg/Kg) inhibited tumor growing to a certain degree. However, the combination of 330 AMP-001 and doxorubicin was more effective in reducing tumor burden ( Fig 7A) . The tumor volume and 331 tumor weight in the combinational group was significantly lower than either doxorubicin or AMP-001. (Fig   332  7B , p < 0.001). Additionally, all mice did not undergo obvious body weight loss or abnormal symptoms in 333 drug treatments ( Fig 7D) . In alternate studies on AMP-001 in triple negative breast cancer model, we have 334 shown that high dose of AMP-001 (~200 mg/Kg) alone can have significant tumor regression with no 335 observable toxicity, despite higher dose 12 . Similarly, in the current studies also, there was no evident 336 histopathological abnormalities were observed in the vital organs such as heart, liver and kidney estimated 337 by HE staining (Fig 8) . Ki67 (marker for cell proliferation) and CD31 (marker for micro vessel density)
338
were also examined by immunohistochemistry in the excised tumor sections. Although, doxorubicin also 339 downregulated the Ki67 expression, the combination group was most effective similar to the tumor 340 regression studies. The trend of CD31 expression was consistent with Ki67 (Fig 8) . In order to determine excised tumors were also subjected to TUNEL assay. The results showed AMP-001 together with 343 doxorubicin treatment had more TUNEL positive cells compared to either doxorubicin or AMP-001 ( Fig   344  8) . In summary, the combination of doxorubicin and AMP-001 yielded a superior response compared to 345 either AMP-001 or doxorubicin in xenograft gastric cancer animal model. Fig 9C) . This pattern of normal beating for cardiomyocytes was seen at all 357 concentrations including 250 µM AMP-001 ( Fig 9D) . AMP-001 showed IC-50 greater than 250 µM, 358 compared to dox at 9.6 µM (25 times less, Fig 9F) which indicates a better safety profile for AMP-359 001. Even FDA approved drug (Sorafinib ~ 40 µM) has lower IC-50 compared to AMP-001 ( Fig 9E) .
360
It is to be noted that IC-50 for cardiomyocytes has to be high (measure of safety) in contrast with IC- 
379
The present study proposes targeting the chemotherapeutics using a tumor specific biomarker 380 Cathespin B. Cathepsin B is overexpressed in many cancers including gastric cancer making it a unique 381 biomarker of cancer to which drugs can be targeted 21 . Valine-citrulline dipeptide is one such linker which 382 is cleavable by Cathespsin B 20 . The drug design AMP-001 has to take into consideration the release of 383 apoptogen (apoptosis inducing ligand) at tumor sites in order to be selective to cancer cells. The pegylation 384 of the basic apoptogen core is expected to increase water solubility and make it stable in the circulatory 385 blood for a long time to reach the tumor 37 . The parent molecule -tocopheryl succinate (-TOS), although 386 showed high promise in both in vitro and in vivo, low solubility in water and a serious toxicity in 387 immunocompetent animal model limited its utility 23 . This observation could explain the lack of clinical 388 product so far for -TOS. This prompted us to redesign apoptogen keeping in mind with a targeting moiety, 389 selectivity and high solubility in water.
390
Most clinically used chemotherapeutics are not selective to cancer. Moreover, these drugs do not 391 address the fundamental aberrations of cancer cells ability to circumvent interventions by dysregulating cell 392 death pathways and desensitize themselves to intervention, irrespective of nature and/or mode of 393 intervention. Hence, our first approach was to sensitize the low or non-responsive tumor cells by activating 394 CD95 pathway, one of the major dysregulated cell death pathways. The second approach was to take 395 advantage of activation technology to ascertain if it entitles synergy with the standard chemotherapeutics.
396
The significant decrease of IC 50 for the combination of doxorubicin and AMP-001 for gastric cancer cells 397 (Fig 3-4 ) reveals that lower dose of doxorubicin could be clinically useful if AMP-001 is used as 398 neoadjuvant to chemotherapy. The tumor cells were pretreated for 6-12 hrs. depending upon cancer cell 399 type and allow the activation of CD95 before we administer chemotherapy. Several vitamin E (VE) 400 analogues, such as α-TOS, α-TOH and VES have been documented as combinations with 401 chemotherapeutics, such as doxorubicin, statins 38 , gefitinib 39 , celecoxib 40 , SU11274 41 , GW966 42 , oridonin 43 402 and baicalein 44 for potential synergetic effects. However, our leading compound AMP-001 is different from 403 the others in terms of ability to target cancer cells sparing normal cells. Activation of cell death pathways 404 in normal cells, for example in brain leads to neuro degenerative diseases 13 and hence, targeting is essential.
405
Our preclinical studies in vitro and in vivo revealed that AMP-001 has dual effects; at low dose it acts 406 as a tumor sensitizer inducting a reasonable cell death while, at higher doses it shows anti-tumorigenicity 407 on its own with little or no observable toxicity in non-target organs 12 . However, for our current studies we 408 used AMP-001 as a tumor sensitizer. The main objective is to enhance the efficacy of the currently used 409 chemotherapeutics using AMP-001 as a neoadjuvant to chemotherapy. The evidence showed that AMP-410 001 synergized with doxorubicin and thereby, circumvents the cells which are resistant to doxorubicin in 411 human gastric cancer cells. Since doxorubicin is a first-line chemotherapeutic agent in clinical cancer 412 treatments but limited in its use due its cardiotoxicity, the combination of doxorubicin and AMP-001 may
